Equipment shortage and overpriced APIs pinch the pharma industry
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The focus is on wellness and personal care products
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
The trial will be conducted across eight sites in Maharashtra
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
The company has been sold to Shinshin Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated